Larvol Delta - Anthos-Therapeutics-Shares-New-Data-from-the-Landmark-AZALEATIMI-71-Study-Demonstrating-the-Factor-XI-Inhibitor-Abelacimab-Signicantly-Reduced-Bleeding-in-Patients-Regardless-of-Age-or-Bleeding-Risk

abelacimab (MAA868) - Novartis

https://www.globenewswire.com/news-release/2025/03/29/3051766/0/en/Anthos-Therapeutics-Shares-New-Data-from-the-Landmark-AZALEA-TIMI-71-Study-Demonstrating-the-Factor-XI-Inhibitor-Abelacimab-Significantly-Reduced-Bleeding-in-Patients-Regardless-of.html

Mar 29, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next